CellSeed Inc. develops cell sheet regenerative medicines. It is involved in the research, development, and commercialization of cell-sheet regenerative medicine products, such as epithelial cell sheet for esophageal regeneration, regenerated cartilage sheet, and chondrocyte sheet for the treatment of knee osteoarthritis. The company also offers UpCell, a temperature-responsive cell cultureware for cell-sheet engineering; RepCell, a temperature-responsive cell cutureware for cell collection; and HydroCell, a low cell binding cultureware. In addition, it provides peripheral equipment, including ThermoPlate III, a heating element made by a transparent glass plate; and cellZscope, an automated cell monitoring system, as well as contract development and manufacturing services. The company was incorporated in 2001 and is headquartered in Tokyo, Japan.
Metrics to compare | 7776 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship7776PeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | −7.5x | −0.5x | |
PEG Ratio | 0.00 | −0.23 | 0.00 | |
Price/Book | 0.0x | 6.6x | 2.6x | |
Price / LTM Sales | 0.0x | 71.8x | 3.0x | |
Upside (Analyst Target) | 0.0% | 59.1% | 53.8% | |
Fair Value Upside | Unlock | 13.7% | 9.6% | Unlock |